Identification of CXCL13 As a Promising Biomarker for Immune Checkpoint Blockade Therapy and PARP Inhibitor Therapy in Ovarian Cancer
Molecular Biotechnology（2024）
Key words
Ovarian cancer,CXCL13,Homologous recombination deficiency,Immune checkpoint blockade
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined